默沙东

Merck's 15-min chart shows Bollinger Bands Narrowing and KDJ Death Cross.

Merck

JPM26: Biotech M&A Surge, Biogen's Revamp, and Merck's $70B Target

Merck's 15-min chart shows RSI Overbought, KDJ Death Cross.

Amgen

PD-1 Landscape Evolves as Subcutaneous Use Grows and Biosimilars Approach Across Solid Tumors

ImmunityBio's Stock Rebound and Undervalued Status: A DCF Analysis Perspective

Catalyst<ul> <li>Fund flows across all order sizes show positive net inflow trends, indicating institutional and retail support for MRK.</li></ul>Risk<ul> <li>Bearish technical signals such as the MACD Death Cross and multiple RSI Overbought readings suggest ongoing volatility and lack of clear directional momentum.</li> <li>Analyst ratings show a lack of consensus with one Buy, one Strong Buy, and one Neutral rating, indicating mixed institutional expectations.</li> <li>News coverage highlights regulatory and pricing pressures on the pharmaceutical sector, which could weigh on MRK's profitability and long-term innovation incentives.</li></ul>

Key Factors

Merck raises long-term revenue outlook to $70 billion by mid-2030s driven by 10 major programs and plans to expand through multi-billion-dollar acquisitions. Merck's Keytruda remains strongly preferred in NSCLC and melanoma as biosimilars approach PD-1/PD-L1 markets, with subcutaneous use growing among oncologists. Merck faces a patent lawsuit from Halozyme related to the launch of Keytruda SC, positioning the legal battle as a major pharmaceutical news cycle event. Merck joins Illumina's Billion Cell Atlas alliance with AstraZeneca and Eli Lilly to accelerate AI-driven drug discovery through genome-wide data mapping.

Recent Updates

MRK News